Analyst Price Target is $17.67
▲ +114.92% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Mind Medicine (MindMed) in the last 3 months. The average price target is $17.67, with a high forecast of $35.00 and a low forecast of $7.00. The average price target represents a 114.92% upside from the last price of $8.22.
Current Consensus is
Buy
The current consensus among 7 investment analysts is to buy stock in Mind Medicine (MindMed). This Buy consensus rating has held steady for over two years.
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Read More